Prostate Cancer Cell Line Characterization

The human prostate carcinoma cell lines LNCaP (RRID: CVCL_1379), VCaP (RRID: CVCL_2235), PC3 (RRID: CVCL_0035), 22Rv1 (RRID: CVCL_1045) and C4-2B (RRID: CVCL_4784) were obtained from the ATCC. LNCaP-V16D, LNCaP-MR49F, and CWR-R1-D567 have been described previously (16, 17 ). Luciferase-labelled RM1, a murine syngeneic model of bone-metastatic prostate cancer, has been described previously (18 (link)). C4-2B, 22Rv1, LNCaP, and LNCaP-V16D cells were maintained in RPMI1640 (Sigma-Aldrich) containing 10% FBS and 2 mmol/L l-Glutamine. PC3 cells were cultured in RPMI1640 containing 5% FBS and 2 mmol/L l-Glutamine. LNCaP-MR42D and LNCaP-MR49F were maintained in RPMI1640 containing 10% FBS, 10 μmol/L enzalutamide, and 2 mmol/L l-Glutamine. CWR-R1-D567 cells were maintained in RPMI1640 containing 10% charcoal-stripped serum and 2 mmol/L l-Glutamine. VCaP cells were maintained in DMEM (high glucose) containing 10% FBS, 2 mmol/L l-Glutamine, 2 mmol/L sodium pyruvate, and 2 mmol/L of nonessential amino acids solution (Sigma-Aldrich). All cell lines were authenticated by short tandem repeat profiling by CellBank Australia in 2017–2020 and were regularly screened for potential Mycoplasma contamination.